5,617 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Flagship Wealth Advisors LLC

Flagship Wealth Advisors LLC acquired a new position in Bristol-Myers Squibb (NYSE:BMY) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 5,617 shares of the biopharmaceutical company’s stock, valued at approximately $318,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wealth Architects LLC boosted its stake in Bristol-Myers Squibb by 5.3% during the 4th quarter. Wealth Architects LLC now owns 5,965 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 302 shares in the last quarter. Cozad Asset Management Inc. boosted its stake in Bristol-Myers Squibb by 7.3% during the 4th quarter. Cozad Asset Management Inc. now owns 6,407 shares of the biopharmaceutical company’s stock valued at $362,000 after purchasing an additional 435 shares in the last quarter. Horizon Kinetics Asset Management LLC boosted its stake in Bristol-Myers Squibb by 1.8% during the 4th quarter. Horizon Kinetics Asset Management LLC now owns 60,476 shares of the biopharmaceutical company’s stock valued at $3,421,000 after purchasing an additional 1,094 shares in the last quarter. 1ST Source Bank boosted its stake in Bristol-Myers Squibb by 1.9% during the 4th quarter. 1ST Source Bank now owns 30,579 shares of the biopharmaceutical company’s stock valued at $1,730,000 after purchasing an additional 572 shares in the last quarter. Finally, Signaturefd LLC boosted its stake in Bristol-Myers Squibb by 3.6% during the 4th quarter. Signaturefd LLC now owns 102,783 shares of the biopharmaceutical company’s stock valued at $5,813,000 after purchasing an additional 3,609 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Trading Down 2.1 %

NYSE BMY opened at $59.01 on Monday. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The company has a market capitalization of $119.75 billion, a PE ratio of -13.35, a price-to-earnings-growth ratio of 2.07 and a beta of 0.43. The firm’s fifty day simple moving average is $57.81 and its 200-day simple moving average is $55.61.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. As a group, sell-side analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.20%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -56.11%.

Analyst Ratings Changes

A number of equities analysts have issued reports on BMY shares. Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and increased their price target for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Bank of America reiterated a “neutral” rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Wells Fargo & Company increased their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Friday, February 7th. Cantor Fitzgerald increased their price objective on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Finally, Citigroup increased their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a research report on Tuesday, January 28th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $57.86.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,823 shares of the stock in a transaction on Friday, February 14th. The shares were purchased at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the transaction, the executive vice president now directly owns 63,932 shares of the company’s stock, valued at $3,506,030.88. This represents a 2.94 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.09% of the stock is currently owned by company insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.